Development of novel high sensitivity cellular assays to complement artificial-intelligence-based rational design of small molecule protein inhibitors

开发能够修饰或抑制某些蛋白质的特定小分子是许多部门至关重要的技术，其应用范围从生物医学部门的药物化合物到工业化学品制造中使用的小分子抑制剂。迄今为止，小分子抑制剂或蛋白质功能调节剂的鉴定是通过资源密集型过程进行的，包括在实验室中筛选大型化合物文库。Cyclica公司开发了突破性的新人工智能技术，可以通过筛选小分子和蛋白质之间的相互作用来设计合理的药物，而成本只是实验室筛选分析的一小部分。Cyclica公司现在寻求与Ryerson大学的Costin Antonescu博士合作，并以NSERC参与资助的形式支持开发新颖，高灵敏度的实验室细胞分析，以补充其现有的分子设计管道。这些新的分析将允许在体外评估在硅设计的小分子对蛋白质和细胞功能的活性。此外，这些检测将允许实时评估小分子对大量单个细胞的作用，这将是高度敏感的，并且代表了Cyclica公司的前沿，下一代变革技术。这代表了Cyclica公司的重大进步和巨大的竞争优势，同时也是这家加拿大公司领导和创造高水平研究和营销职位的机会。****

The development of specific small molecules that can modify or inhibit certain proteins represents critically important technology for many sectors, with applications ranging from drug compounds in the biomedical sector to small molecule inhibitors for use in industrial chemical manufacture. The identification of small molecule inhibitors or modifiers of protein function has to date been performed by resource-intensive processes involving screening of large libraries of chemical compounds in the laboratory. Cyclica Inc. has developed groundbreaking new artificial intelligence technology that allows rational drug design by the screening of interactions between small molecules and proteins in silico, at a fraction of the cost of laboratory screening assays. Cyclica Inc. now seeks a partnership with Dr. Costin Antonescu at Ryerson University and support in the form of this NSERC Engage grant to develop novel, highly sensitive laboratory cell-based assays to complement its existing molecular design pipeline. These new assays will allow assessment of the activity of the in silico designed small molecules on protein and cellular function in vitro. Moreover, these assays will allow assessment of the action of the small molecules on large numbers of individual cells in real time, as will be highly sensitive and represent cutting-edge, next generation transformative technology for Cyclica Inc. This represents a significant advancement and a large competitive for advantage Cyclica Inc., and as such an opportunity for this Canadian company to lead and to create high-level research and marketing positions.****